New Hope Against Malaria, GSK and MMV Introduce Revolutionary Single-Dose Treatment

GSK plc and Medicines for Malaria Venture (MMV) have introduced a groundbreaking single-dose medication to prevent the recurrence of Plasmodium vivax (P. vivax) malaria. Tafenoquine, in combination with chloroquine for radical cure, is now available in Thailand and Brazil, marking a significant stride in malaria eradication efforts.

P. vivax, prevalent across most regions beyond sub-Saharan Africa, poses a distinctive challenge due to its tendency for clinical relapses. Without treatment of the dormant liver-stage infection, patients experience recurrent bouts of illness, exacting a heavy toll on their physical well-being, economic stability, and social fabric. This cycle perpetuates poverty within communities affected by the parasite. Severe cases can escalate to fatal outcomes, amplifying the disease burden and enhancing transmission risks, thus hindering global endeavors aimed at malaria eradication.

Tafenoquine, an 8-aminoquinoline antimalarial, targets the liver-stage of P. vivax malaria. When paired with chloroquine for the blood-stage infection, it achieves radical cure, effectively treating both stages of the disease. However, due to its class characteristics, tafenoquine can induce acute haemolytic anaemia in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Therefore, a G6PD test is imperative before prescribing tafenoquine to ensure safe administration.

Both Thailand and Brazil's Ministries of Health have supported feasibility studies, sponsored in collaboration with MMV, to assess the practicality of integrating tafenoquine into their public health systems following point-of-care G6PD testing. Insights gleaned from these real-world studies have guided their decisions to incorporate these antimalarial strategies, bolstering their efforts towards malaria elimination.